Home Healthcare Biotechnology Prostate Cancer Diagnostics Market

Prostate Cancer Diagnostics Market Size, Share & Trends Analysis Report By Test Type (Preliminary Tests, Confirmatory Tests), By Type (Adenocarcinoma, Interstitial Cell Carcinoma, Other), By End Use (Hospitals, Outpatient Facilities, Home Care, Others) and By Country (U.S., Canada) Forecasts, 2026-2034

Last Updated: July 09, 2026 | Author: Debashree B | Format: | Report Code: SR4791DR | Pages: 110
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. Prostate Cancer Diagnostics Market, By Test Type 2022-2034 (USD MILLION/ Units)
    1. Preliminary Tests
      1. PSA Tests
      2. Free PSA Test
      3. Total PSA Test
      4. Other Preliminary Tests
    2. Confirmatory Tests
      1. Pca3 Test
      2. Trans-Rectal Ultrasound
      3. Biopsy Test
  2. Prostate Cancer Diagnostics Market, By Type 2022-2034 (USD MILLION/ Units)
    1. Adenocarcinoma
    2. Interstitial Cell Carcinoma
    3. Other
  3. Prostate Cancer Diagnostics Market, By End Use 2022-2034 (USD MILLION/ Units)
    1. Hospitals
    2. Outpatient Facilities
    3. Home Care
    4. Others
  4. Regional Prostate Cancer Diagnostics Market
    1. North America
      1. North America Prostate Cancer Diagnostics Market By Test Type 2022-2034 (USD MILLION/ Units)
        1. Preliminary Tests
          1. PSA Tests
          2. Free PSA Test
          3. Total PSA Test
          4. Other Preliminary Tests
        2. Confirmatory Tests
          1. Pca3 Test
          2. Trans-Rectal Ultrasound
          3. Biopsy Test
      2. North America Prostate Cancer Diagnostics Market By Type 2022-2034 (USD MILLION/ Units)
        1. Adenocarcinoma
        2. Interstitial Cell Carcinoma
        3. Other
      3. North America Prostate Cancer Diagnostics Market By End Use 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Outpatient Facilities
        3. Home Care
        4. Others
      4. U.S.
        1. Preliminary Tests
          1. PSA Tests
          2. Free PSA Test
          3. Total PSA Test
          4. Other Preliminary Tests
        2. Confirmatory Tests
          1. Pca3 Test
          2. Trans-Rectal Ultrasound
          3. Biopsy Test
        3. Adenocarcinoma
        4. Interstitial Cell Carcinoma
        5. Other
        6. Hospitals
        7. Outpatient Facilities
        8. Home Care
        9. Others
      5. Canada
        1. Preliminary Tests
          1. PSA Tests
          2. Free PSA Test
          3. Total PSA Test
          4. Other Preliminary Tests
        2. Confirmatory Tests
          1. Pca3 Test
          2. Trans-Rectal Ultrasound
          3. Biopsy Test
        3. Adenocarcinoma
        4. Interstitial Cell Carcinoma
        5. Other
        6. Hospitals
        7. Outpatient Facilities
        8. Home Care
        9. Others
    2. Europe
      1. Europe Prostate Cancer Diagnostics Market By Test Type 2022-2034 (USD MILLION/ Units)
        1. Preliminary Tests
          1. PSA Tests
          2. Free PSA Test
          3. Total PSA Test
          4. Other Preliminary Tests
        2. Confirmatory Tests
          1. Pca3 Test
          2. Trans-Rectal Ultrasound
          3. Biopsy Test
      2. Europe Prostate Cancer Diagnostics Market By Type 2022-2034 (USD MILLION/ Units)
        1. Adenocarcinoma
        2. Interstitial Cell Carcinoma
        3. Other
      3. Europe Prostate Cancer Diagnostics Market By End Use 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Outpatient Facilities
        3. Home Care
        4. Others
      4. U.K.
        1. Preliminary Tests
          1. PSA Tests
          2. Free PSA Test
          3. Total PSA Test
          4. Other Preliminary Tests
        2. Confirmatory Tests
          1. Pca3 Test
          2. Trans-Rectal Ultrasound
          3. Biopsy Test
        3. Adenocarcinoma
        4. Interstitial Cell Carcinoma
        5. Other
        6. Hospitals
        7. Outpatient Facilities
        8. Home Care
        9. Others
      5. Germany
        1. Preliminary Tests
          1. PSA Tests
          2. Free PSA Test
          3. Total PSA Test
          4. Other Preliminary Tests
        2. Confirmatory Tests
          1. Pca3 Test
          2. Trans-Rectal Ultrasound
          3. Biopsy Test
        3. Adenocarcinoma
        4. Interstitial Cell Carcinoma
        5. Other
        6. Hospitals
        7. Outpatient Facilities
        8. Home Care
        9. Others
      6. France
        1. Preliminary Tests
          1. PSA Tests
          2. Free PSA Test
          3. Total PSA Test
          4. Other Preliminary Tests
        2. Confirmatory Tests
          1. Pca3 Test
          2. Trans-Rectal Ultrasound
          3. Biopsy Test
        3. Adenocarcinoma
        4. Interstitial Cell Carcinoma
        5. Other
        6. Hospitals
        7. Outpatient Facilities
        8. Home Care
        9. Others
      7. Spain
        1. Preliminary Tests
          1. PSA Tests
          2. Free PSA Test
          3. Total PSA Test
          4. Other Preliminary Tests
        2. Confirmatory Tests
          1. Pca3 Test
          2. Trans-Rectal Ultrasound
          3. Biopsy Test
        3. Adenocarcinoma
        4. Interstitial Cell Carcinoma
        5. Other
        6. Hospitals
        7. Outpatient Facilities
        8. Home Care
        9. Others
      8. Italy
        1. Preliminary Tests
          1. PSA Tests
          2. Free PSA Test
          3. Total PSA Test
          4. Other Preliminary Tests
        2. Confirmatory Tests
          1. Pca3 Test
          2. Trans-Rectal Ultrasound
          3. Biopsy Test
        3. Adenocarcinoma
        4. Interstitial Cell Carcinoma
        5. Other
        6. Hospitals
        7. Outpatient Facilities
        8. Home Care
        9. Others
      9. Russia
        1. Preliminary Tests
          1. PSA Tests
          2. Free PSA Test
          3. Total PSA Test
          4. Other Preliminary Tests
        2. Confirmatory Tests
          1. Pca3 Test
          2. Trans-Rectal Ultrasound
          3. Biopsy Test
        3. Adenocarcinoma
        4. Interstitial Cell Carcinoma
        5. Other
        6. Hospitals
        7. Outpatient Facilities
        8. Home Care
        9. Others
      10. Nordic
        1. Preliminary Tests
          1. PSA Tests
          2. Free PSA Test
          3. Total PSA Test
          4. Other Preliminary Tests
        2. Confirmatory Tests
          1. Pca3 Test
          2. Trans-Rectal Ultrasound
          3. Biopsy Test
        3. Adenocarcinoma
        4. Interstitial Cell Carcinoma
        5. Other
        6. Hospitals
        7. Outpatient Facilities
        8. Home Care
        9. Others
      11. Benelux
        1. Preliminary Tests
          1. PSA Tests
          2. Free PSA Test
          3. Total PSA Test
          4. Other Preliminary Tests
        2. Confirmatory Tests
          1. Pca3 Test
          2. Trans-Rectal Ultrasound
          3. Biopsy Test
        3. Adenocarcinoma
        4. Interstitial Cell Carcinoma
        5. Other
        6. Hospitals
        7. Outpatient Facilities
        8. Home Care
        9. Others
      12. Rest of Europe
        1. Preliminary Tests
          1. PSA Tests
          2. Free PSA Test
          3. Total PSA Test
          4. Other Preliminary Tests
        2. Confirmatory Tests
          1. Pca3 Test
          2. Trans-Rectal Ultrasound
          3. Biopsy Test
        3. Adenocarcinoma
        4. Interstitial Cell Carcinoma
        5. Other
        6. Hospitals
        7. Outpatient Facilities
        8. Home Care
        9. Others
    3. APAC
      1. APAC Prostate Cancer Diagnostics Market By Test Type 2022-2034 (USD MILLION/ Units)
        1. Preliminary Tests
          1. PSA Tests
          2. Free PSA Test
          3. Total PSA Test
          4. Other Preliminary Tests
        2. Confirmatory Tests
          1. Pca3 Test
          2. Trans-Rectal Ultrasound
          3. Biopsy Test
      2. APAC Prostate Cancer Diagnostics Market By Type 2022-2034 (USD MILLION/ Units)
        1. Adenocarcinoma
        2. Interstitial Cell Carcinoma
        3. Other
      3. APAC Prostate Cancer Diagnostics Market By End Use 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Outpatient Facilities
        3. Home Care
        4. Others
      4. China
        1. Preliminary Tests
          1. PSA Tests
          2. Free PSA Test
          3. Total PSA Test
          4. Other Preliminary Tests
        2. Confirmatory Tests
          1. Pca3 Test
          2. Trans-Rectal Ultrasound
          3. Biopsy Test
        3. Adenocarcinoma
        4. Interstitial Cell Carcinoma
        5. Other
        6. Hospitals
        7. Outpatient Facilities
        8. Home Care
        9. Others
      5. Korea
        1. Preliminary Tests
          1. PSA Tests
          2. Free PSA Test
          3. Total PSA Test
          4. Other Preliminary Tests
        2. Confirmatory Tests
          1. Pca3 Test
          2. Trans-Rectal Ultrasound
          3. Biopsy Test
        3. Adenocarcinoma
        4. Interstitial Cell Carcinoma
        5. Other
        6. Hospitals
        7. Outpatient Facilities
        8. Home Care
        9. Others
      6. Japan
        1. Preliminary Tests
          1. PSA Tests
          2. Free PSA Test
          3. Total PSA Test
          4. Other Preliminary Tests
        2. Confirmatory Tests
          1. Pca3 Test
          2. Trans-Rectal Ultrasound
          3. Biopsy Test
        3. Adenocarcinoma
        4. Interstitial Cell Carcinoma
        5. Other
        6. Hospitals
        7. Outpatient Facilities
        8. Home Care
        9. Others
      7. India
        1. Preliminary Tests
          1. PSA Tests
          2. Free PSA Test
          3. Total PSA Test
          4. Other Preliminary Tests
        2. Confirmatory Tests
          1. Pca3 Test
          2. Trans-Rectal Ultrasound
          3. Biopsy Test
        3. Adenocarcinoma
        4. Interstitial Cell Carcinoma
        5. Other
        6. Hospitals
        7. Outpatient Facilities
        8. Home Care
        9. Others
      8. Australia
        1. Preliminary Tests
          1. PSA Tests
          2. Free PSA Test
          3. Total PSA Test
          4. Other Preliminary Tests
        2. Confirmatory Tests
          1. Pca3 Test
          2. Trans-Rectal Ultrasound
          3. Biopsy Test
        3. Adenocarcinoma
        4. Interstitial Cell Carcinoma
        5. Other
        6. Hospitals
        7. Outpatient Facilities
        8. Home Care
        9. Others
      9. Singapore
        1. Preliminary Tests
          1. PSA Tests
          2. Free PSA Test
          3. Total PSA Test
          4. Other Preliminary Tests
        2. Confirmatory Tests
          1. Pca3 Test
          2. Trans-Rectal Ultrasound
          3. Biopsy Test
        3. Adenocarcinoma
        4. Interstitial Cell Carcinoma
        5. Other
        6. Hospitals
        7. Outpatient Facilities
        8. Home Care
        9. Others
      10. Taiwan
        1. Preliminary Tests
          1. PSA Tests
          2. Free PSA Test
          3. Total PSA Test
          4. Other Preliminary Tests
        2. Confirmatory Tests
          1. Pca3 Test
          2. Trans-Rectal Ultrasound
          3. Biopsy Test
        3. Adenocarcinoma
        4. Interstitial Cell Carcinoma
        5. Other
        6. Hospitals
        7. Outpatient Facilities
        8. Home Care
        9. Others
      11. South East Asia
        1. Preliminary Tests
          1. PSA Tests
          2. Free PSA Test
          3. Total PSA Test
          4. Other Preliminary Tests
        2. Confirmatory Tests
          1. Pca3 Test
          2. Trans-Rectal Ultrasound
          3. Biopsy Test
        3. Adenocarcinoma
        4. Interstitial Cell Carcinoma
        5. Other
        6. Hospitals
        7. Outpatient Facilities
        8. Home Care
        9. Others
      12. Rest of Asia-Pacific
        1. Preliminary Tests
          1. PSA Tests
          2. Free PSA Test
          3. Total PSA Test
          4. Other Preliminary Tests
        2. Confirmatory Tests
          1. Pca3 Test
          2. Trans-Rectal Ultrasound
          3. Biopsy Test
        3. Adenocarcinoma
        4. Interstitial Cell Carcinoma
        5. Other
        6. Hospitals
        7. Outpatient Facilities
        8. Home Care
        9. Others
    4. Middle East and Africa
      1. Middle East and Africa Prostate Cancer Diagnostics Market By Test Type 2022-2034 (USD MILLION/ Units)
        1. Preliminary Tests
          1. PSA Tests
          2. Free PSA Test
          3. Total PSA Test
          4. Other Preliminary Tests
        2. Confirmatory Tests
          1. Pca3 Test
          2. Trans-Rectal Ultrasound
          3. Biopsy Test
      2. Middle East and Africa Prostate Cancer Diagnostics Market By Type 2022-2034 (USD MILLION/ Units)
        1. Adenocarcinoma
        2. Interstitial Cell Carcinoma
        3. Other
      3. Middle East and Africa Prostate Cancer Diagnostics Market By End Use 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Outpatient Facilities
        3. Home Care
        4. Others
      4. UAE
        1. Preliminary Tests
          1. PSA Tests
          2. Free PSA Test
          3. Total PSA Test
          4. Other Preliminary Tests
        2. Confirmatory Tests
          1. Pca3 Test
          2. Trans-Rectal Ultrasound
          3. Biopsy Test
        3. Adenocarcinoma
        4. Interstitial Cell Carcinoma
        5. Other
        6. Hospitals
        7. Outpatient Facilities
        8. Home Care
        9. Others
      5. Turkey
        1. Preliminary Tests
          1. PSA Tests
          2. Free PSA Test
          3. Total PSA Test
          4. Other Preliminary Tests
        2. Confirmatory Tests
          1. Pca3 Test
          2. Trans-Rectal Ultrasound
          3. Biopsy Test
        3. Adenocarcinoma
        4. Interstitial Cell Carcinoma
        5. Other
        6. Hospitals
        7. Outpatient Facilities
        8. Home Care
        9. Others
      6. Saudi Arabia
        1. Preliminary Tests
          1. PSA Tests
          2. Free PSA Test
          3. Total PSA Test
          4. Other Preliminary Tests
        2. Confirmatory Tests
          1. Pca3 Test
          2. Trans-Rectal Ultrasound
          3. Biopsy Test
        3. Adenocarcinoma
        4. Interstitial Cell Carcinoma
        5. Other
        6. Hospitals
        7. Outpatient Facilities
        8. Home Care
        9. Others
      7. South Africa
        1. Preliminary Tests
          1. PSA Tests
          2. Free PSA Test
          3. Total PSA Test
          4. Other Preliminary Tests
        2. Confirmatory Tests
          1. Pca3 Test
          2. Trans-Rectal Ultrasound
          3. Biopsy Test
        3. Adenocarcinoma
        4. Interstitial Cell Carcinoma
        5. Other
        6. Hospitals
        7. Outpatient Facilities
        8. Home Care
        9. Others
      8. Egypt
        1. Preliminary Tests
          1. PSA Tests
          2. Free PSA Test
          3. Total PSA Test
          4. Other Preliminary Tests
        2. Confirmatory Tests
          1. Pca3 Test
          2. Trans-Rectal Ultrasound
          3. Biopsy Test
        3. Adenocarcinoma
        4. Interstitial Cell Carcinoma
        5. Other
        6. Hospitals
        7. Outpatient Facilities
        8. Home Care
        9. Others
      9. Nigeria
        1. Preliminary Tests
          1. PSA Tests
          2. Free PSA Test
          3. Total PSA Test
          4. Other Preliminary Tests
        2. Confirmatory Tests
          1. Pca3 Test
          2. Trans-Rectal Ultrasound
          3. Biopsy Test
        3. Adenocarcinoma
        4. Interstitial Cell Carcinoma
        5. Other
        6. Hospitals
        7. Outpatient Facilities
        8. Home Care
        9. Others
      10. Rest of MEA
        1. Preliminary Tests
          1. PSA Tests
          2. Free PSA Test
          3. Total PSA Test
          4. Other Preliminary Tests
        2. Confirmatory Tests
          1. Pca3 Test
          2. Trans-Rectal Ultrasound
          3. Biopsy Test
        3. Adenocarcinoma
        4. Interstitial Cell Carcinoma
        5. Other
        6. Hospitals
        7. Outpatient Facilities
        8. Home Care
        9. Others
    5. LATAM
      1. LATAM Prostate Cancer Diagnostics Market By Test Type 2022-2034 (USD MILLION/ Units)
        1. Preliminary Tests
          1. PSA Tests
          2. Free PSA Test
          3. Total PSA Test
          4. Other Preliminary Tests
        2. Confirmatory Tests
          1. Pca3 Test
          2. Trans-Rectal Ultrasound
          3. Biopsy Test
      2. LATAM Prostate Cancer Diagnostics Market By Type 2022-2034 (USD MILLION/ Units)
        1. Adenocarcinoma
        2. Interstitial Cell Carcinoma
        3. Other
      3. LATAM Prostate Cancer Diagnostics Market By End Use 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Outpatient Facilities
        3. Home Care
        4. Others
      4. Brazil
        1. Preliminary Tests
          1. PSA Tests
          2. Free PSA Test
          3. Total PSA Test
          4. Other Preliminary Tests
        2. Confirmatory Tests
          1. Pca3 Test
          2. Trans-Rectal Ultrasound
          3. Biopsy Test
        3. Adenocarcinoma
        4. Interstitial Cell Carcinoma
        5. Other
        6. Hospitals
        7. Outpatient Facilities
        8. Home Care
        9. Others
      5. Mexico
        1. Preliminary Tests
          1. PSA Tests
          2. Free PSA Test
          3. Total PSA Test
          4. Other Preliminary Tests
        2. Confirmatory Tests
          1. Pca3 Test
          2. Trans-Rectal Ultrasound
          3. Biopsy Test
        3. Adenocarcinoma
        4. Interstitial Cell Carcinoma
        5. Other
        6. Hospitals
        7. Outpatient Facilities
        8. Home Care
        9. Others
      6. Argentina
        1. Preliminary Tests
          1. PSA Tests
          2. Free PSA Test
          3. Total PSA Test
          4. Other Preliminary Tests
        2. Confirmatory Tests
          1. Pca3 Test
          2. Trans-Rectal Ultrasound
          3. Biopsy Test
        3. Adenocarcinoma
        4. Interstitial Cell Carcinoma
        5. Other
        6. Hospitals
        7. Outpatient Facilities
        8. Home Care
        9. Others
      7. Chile
        1. Preliminary Tests
          1. PSA Tests
          2. Free PSA Test
          3. Total PSA Test
          4. Other Preliminary Tests
        2. Confirmatory Tests
          1. Pca3 Test
          2. Trans-Rectal Ultrasound
          3. Biopsy Test
        3. Adenocarcinoma
        4. Interstitial Cell Carcinoma
        5. Other
        6. Hospitals
        7. Outpatient Facilities
        8. Home Care
        9. Others
      8. Colombia
        1. Preliminary Tests
          1. PSA Tests
          2. Free PSA Test
          3. Total PSA Test
          4. Other Preliminary Tests
        2. Confirmatory Tests
          1. Pca3 Test
          2. Trans-Rectal Ultrasound
          3. Biopsy Test
        3. Adenocarcinoma
        4. Interstitial Cell Carcinoma
        5. Other
        6. Hospitals
        7. Outpatient Facilities
        8. Home Care
        9. Others
      9. Rest of LATAM
        1. Preliminary Tests
          1. PSA Tests
          2. Free PSA Test
          3. Total PSA Test
          4. Other Preliminary Tests
        2. Confirmatory Tests
          1. Pca3 Test
          2. Trans-Rectal Ultrasound
          3. Biopsy Test
        3. Adenocarcinoma
        4. Interstitial Cell Carcinoma
        5. Other
        6. Hospitals
        7. Outpatient Facilities
        8. Home Care
        9. Others
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.